Anzeige
Mehr »
Mittwoch, 27.08.2025 - Börsentäglich über 12.000 News
Patentschutz bis in die 2040er - Biotech-Geheimtipp vor möglichem Fast-Track-Durchbruch in den USA!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 565131 | ISIN: DK0010272202 | Ticker-Symbol: GE9
Tradegate
27.08.25 | 19:01
212,70 Euro
+0,61 % +1,30
1-Jahres-Chart
GENMAB A/S Chart 1 Jahr
5-Tage-Chart
GENMAB A/S 5-Tage-Chart
RealtimeGeldBriefZeit
211,70213,6019:09
211,70213,6019:09

Aktuelle News zur GENMAB Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
GENMAB Aktie jetzt für 0€ handeln
DiGenmab Gets Breakthrough Therapy Status For Rinatabart Sesutecan In Endometrial Cancer272COPENHAGEN (dpa-AFX) - Genmab A/S (GMAB) Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesutecan for the treatment...
► Artikel lesen
DiGenmab A/S: Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S) in Advanced Endometrial Cancer (EC)259Breakthrough Therapy Designation granted to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer (EC) who have disease progression on or following prior...
► Artikel lesen
20.08.AbbVie/Genmab's lymphoma drug shows promise in phase 3 combination trial16
15.08.Genmab A/S stock price target raised to $36 from $35 at H.C. Wainwright10
12.08.Genmab to increase share capital by 0.01% through employee warrants3
12.08.Genmab erhöht Aktienkapital nach Ausübung von Mitarbeiteroptionen6
12.08.Genmab A/S: Capital Increase in Genmab as a Result of Employee Warrant Exercise4
08.08.Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%25
08.08.Trial results set up AbbVie, Genmab's Epkinly for key expansion in follicular lymphoma14
08.08.Genmab übertrifft Prognosen für Q2 2025 - Aktie legt deutlich zu13
07.08.Genmab hebt nach Gewinnsprung von 56 % die Prognose für 2025 an12
07.08.Genmab H1 2025 slides: 56% profit growth prompts raised guidance14
07.08.Genmab Reports Strong H1 2025 Results Driven By Higher Royalties And Product Sales454COPENHAGEN (dpa-AFX) - Genmab A/S (GMAB) posted performance results on Thursday for the first half of 2025, with revenue rising 19 percent year-over-year to $1.64 billion, up from $1.38 billion...
► Artikel lesen
07.08.Genmab rises on late-stage trial win for AbbVie-partnered lymphoma therapy30
07.08.Genmab reports 1H results6
07.08.Genmab's Epcoritamab Combo Shows Strong Results In Follicular Lymphoma Trial376COPENHAGEN (dpa-AFX) - Genmab A/S (GMAB), Thursday announced positive results from its Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide...
► Artikel lesen
07.08.Genmab A/S: Genmab Announces Financial Results for the First Half of 2025981August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab advancing to earlier lines of therapy with the submission of a sBLA to the FDA for...
► Artikel lesen
07.08.Genmab Announces Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)332Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p 0.0001) and Progression-Free Survival...
► Artikel lesen
07.08.GENMAB A/S - 6-K, Report of foreign issuer6
16.07.GENMAB A/S - 6-K, Report of foreign issuer4
Weiter >>
130 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1